COVID-19 patients who had chronic cardiovascular co-morbidities and administered statins or renin–angiotensin–aldosterone system inhibitors had significantly lower plasma concentrations of IL-6 than COVID-19 patients who did not have any co-morbidities. This evidence concerns the gene IL6 and COVID-19.